Diagonal Bio AB (publ) (DIABIO.ST)
SEK 0.02
(4.18%)
SEK 0.02
(4.18%)
| Breakdown | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Operating Cash Flow | -5.23 Million | -15.77 Million | -10.94 Million | 226.66 Thousand |
| Net Income | -11.67 Million | -16.16 Million | -11.66 Million | -777.33 Thousand |
| Depreciation & Amortization | 3000.00 | - | - | - |
| Deferred income taxes | - | - | - | - |
| Stock-based compensation | - | - | - | - |
| Change in working capital | 6.44 Million | 391 Thousand | 720 Thousand | 1 Million |
| Other non-cash items | -6.44 Million | -390.99 Thousand | -720 Thousand | - |
| Investing Cash Flow | -4.24 Million | -4.95 Million | -8.59 Million | -7.97 Million |
| Investments in PPE | -4.24 Million | -4.95 Million | -8.59 Million | - |
| Acquisitions | - | - | - | - |
| Investment purchases | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - |
| Other Investing Activities | -4.24 Million | -4.95 Million | -8.59 Million | -7.97 Million |
| Financing Cash Flow | -1.13 Million | 13.54 Million | 36.63 Million | 12.63 Million |
| Debt repayment | -2.81 Million | - | - | - |
| Dividends payments | - | - | - | - |
| Common Stock Repurchased | - | - | - | - |
| Common Stock Issuance | 1.67 Million | 13.54 Million | 36.63 Million | - |
| Other Financing Activities | -1.13 Million | 13.54 Million | 36.63 Million | 12.63 Million |
| Accounts receivables | -848 Thousand | -243 Thousand | -344 Thousand | -436 Thousand |
| Accounts payables | 7.29 Million | 634 Thousand | 1.06 Million | - |
| Inventory | - | -634 Thousand | -1.06 Million | - |
| Other working capital | 7.29 Million | 634 Thousand | 1.06 Million | 1.44 Million |
| Cash at beginning of period | 13.58 Million | 20.76 Million | 3.66 Million | -1.22 Million |
| Cash at end of period | 2.97 Million | 13.58 Million | 20.76 Million | 3.66 Million |
| Capital Expenditure | -4.24 Million | -4.95 Million | -8.59 Million | - |
| Effect of forex changes on cash | - | - | - | - |
| Net cash flow / Change in cash | -10.61 Million | -7.18 Million | 17.09 Million | 4.89 Million |
| Free Cash Flow | -9.47 Million | -20.72 Million | -19.53 Million | 226.66 Thousand |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -3.44 Million | -2.98 Million | -11.67 Million | -2.53 Million | -2.65 Million | -2.79 Million |
| Depreciation & Amortization | 354 Thousand | 2000.00 | 3000.00 | 2000.00 | 1000.00 | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | - | 6.44 Million | 6.44 Million | - | - |
| Other non-cash items | -14.3 Million | 9.55 Million | -6.44 Million | 2.49 Million | 2.97 Million | -49 Thousand |
| Investing Cash Flow | -822 Thousand | -541 Thousand | -4.24 Million | -536 Thousand | -1.13 Million | -1.38 Million |
| Investments in PPE | -375 Thousand | - | -4.24 Million | -4.24 Million | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -447 Thousand | -541 Thousand | -4.24 Million | -539 Thousand | -1.13 Million | -1.38 Million |
| Financing Cash Flow | 20.51 Million | -7.14 Million | -1.13 Million | -1.16 Million | - | 32 Thousand |
| Debt repayment | - | - | -2.81 Million | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | 1.67 Million | - | - | - |
| Other Financing Activities | 20.51 Million | -7.14 Million | -1.13 Million | -156 Thousand | - | 32 Thousand |
| Accounts receivables | - | - | -848 Thousand | -848 Thousand | - | - |
| Accounts payables | - | - | 7.29 Million | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | - | - | 7.29 Million | 7.29 Million | - | - |
| Cash at beginning of period | 1.85 Million | 2.97 Million | 13.58 Million | 4.71 Million | 5.53 Million | 9.73 Million |
| Cash at end of period | 4.15 Million | 1.85 Million | 2.97 Million | 2.97 Million | 4.71 Million | 5.53 Million |
| Capital Expenditure | -375 Thousand | - | -4.24 Million | -4.24 Million | - | - |
| Effect of forex changes on cash | - | - | - | 1000.00 | - | - |
| Net cash flow / Change in cash | 2.3 Million | -1.11 Million | -10.61 Million | -1.74 Million | -816 Thousand | -4.2 Million |
| Free Cash Flow | -17.77 Million | 6.56 Million | -9.47 Million | -4.28 Million | 316 Thousand | -2.84 Million |
GENPHARMA
GATE
SPOI
QBAT
HBIE
032350